Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
08:10am, Monday, 09'th Mar 2026
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.
neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:00am, Monday, 02'nd Mar 2026
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patie
Got $300? 2 Biotech Stocks to Buy and Hold Forever
05:48am, Monday, 16'th Feb 2026
Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
11:24pm, Friday, 13'th Feb 2026
SPRY's main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million. My core thesis is that Neffy's more convenient delivery mech
-Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epi
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in
Campbell & CO Investment Adviser LLC Takes Position in ARS Pharmaceuticals, Inc. $SPRY
03:51am, Thursday, 22'nd Jan 2026
Campbell and CO Investment Adviser LLC purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) during the third quarter, according to the company in its most recent Form 13F fil
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
08:00am, Wednesday, 21'st Jan 2026
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biophar
FAS Wealth Partners Inc. Buys 51,460 Shares of ARS Pharmaceuticals, Inc. $SPRY
05:46am, Sunday, 18'th Jan 2026
FAS Wealth Partners Inc. increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 34.5% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The ins
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
12:32pm, Friday, 09'th Jan 2026
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of “Moderate Buy” by Brokerages
01:38am, Friday, 02'nd Jan 2026
Shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, Mar
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a
53,341 Shares in ARS Pharmaceuticals, Inc. $SPRY Purchased by Permanent Capital Management LP
06:24am, Monday, 29'th Dec 2025
Permanent Capital Management LP purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) in the third quarter, according to the company in its most recent 13F filing with the Sec
